TY - JOUR
T1 - Adverse events associated with mohs micrographic surgery
T2 - Multicenter Prospective Cohort Study of 20 821 Casesat 23 Centers
AU - Alam, Murad
AU - Ibrahim, Omer
AU - Nodzenski, Michael
AU - Strasswimmer, John M.
AU - Jiang, Shang I.Brian
AU - Cohen, Joel L.
AU - Albano, Brian J.
AU - Batra, Priya
AU - Behshad, Ramona
AU - Benedetto, Anthony V.
AU - Chan, C. Stanley
AU - Chilukuri, Suneel
AU - Crocker, Courtney
AU - Crystal, Hillary W.
AU - Dhir, Anir
AU - Faulconer, Victoria A.
AU - Goldberg, Leonard H.
AU - Goodman, Chandra
AU - Greenbaum, Steven S.
AU - Hale, Elizabeth K.
AU - Hanke, C. William
AU - Hruza, George J.
AU - Jacobson, Laurie
AU - Jones, Jason
AU - Kimyai-Asadi, Arash
AU - Kouba, David
AU - Lahti, James
AU - Macias, Kristi
AU - Miller, Stanley J.
AU - Monk, Edward
AU - Nguyen, Tri H.
AU - Oganesyan, Gagik
AU - Pennie, Michelle
AU - Pontius, Katherine
AU - Posten, William
AU - Reichel, Jennifer L.
AU - Rohrer, Thomas E.
AU - Rooney, James A.
AU - Tran, Hien T.
AU - Poon, Emily
AU - Bolotin, Diana
AU - Dubina, Meghan
AU - Pace, Natalie
AU - Kim, Natalie
AU - Disphanurat, Wareeporn
AU - Kathawalla, Ummul
AU - Kakar, Rohit
AU - West, Dennis P.
AU - Veledar, Emir
AU - Yoo, Simon
PY - 2013/12
Y1 - 2013/12
N2 - Importance Detailed information regarding perioperative risk and adverse events associated with Mohs micrographic surgery (MMS) can guide clinical management. Much of the data regarding complications ofMMSare anecdotal or report findings from single centers or single events. Objectives To quantify adverse events associated with MMS and detect differences relevant to safety. Design, Setting, And Participants Multicenter prospective inception cohort study of 21 private and 2 institutional US ambulatory referral centers for MMS. Participants were a consecutive sample of patients presenting with MMS for 35 weeks at each center, with staggered start times. Exposure Mohs micrographic surgery. Main Outcomes And Measures Intraoperative and postoperative minor and serious adverse events. Results Among 20 821 MMS procedures, 149 adverse events (0.72%), including 4 serious events (0.02%), and no deaths were reported. Common adverse events reported were infections (61.1%), dehiscence and partial or full necrosis (20.1%), and bleeding and hematoma (15.4%). Most bleeding and wound-healing complications occurred in patients receiving anticoagulation therapy. Use of some antiseptics and antibiotics and sterile gloves during MMS were associated with modest reduction of risk for adverse events. Conclusions And Relevance Mohs micrographic surgery is safe, with a very lowrate of adverse events, an exceedingly low rate of serious adverse events, and an undetectable mortality rate.Commoncomplications include infections, followed by impaired wound healing and bleeding. Bleeding and wound-healing issues are often associated with preexisting anticoagulation therapy, which is nonetheless managed safely duringMMS.We are not certain whether the small effects seen with the use of sterile gloves and antiseptics and antibiotics are clinically significant and whether wide-scale practice changeswould be cost-effective given the small risk reductions.
AB - Importance Detailed information regarding perioperative risk and adverse events associated with Mohs micrographic surgery (MMS) can guide clinical management. Much of the data regarding complications ofMMSare anecdotal or report findings from single centers or single events. Objectives To quantify adverse events associated with MMS and detect differences relevant to safety. Design, Setting, And Participants Multicenter prospective inception cohort study of 21 private and 2 institutional US ambulatory referral centers for MMS. Participants were a consecutive sample of patients presenting with MMS for 35 weeks at each center, with staggered start times. Exposure Mohs micrographic surgery. Main Outcomes And Measures Intraoperative and postoperative minor and serious adverse events. Results Among 20 821 MMS procedures, 149 adverse events (0.72%), including 4 serious events (0.02%), and no deaths were reported. Common adverse events reported were infections (61.1%), dehiscence and partial or full necrosis (20.1%), and bleeding and hematoma (15.4%). Most bleeding and wound-healing complications occurred in patients receiving anticoagulation therapy. Use of some antiseptics and antibiotics and sterile gloves during MMS were associated with modest reduction of risk for adverse events. Conclusions And Relevance Mohs micrographic surgery is safe, with a very lowrate of adverse events, an exceedingly low rate of serious adverse events, and an undetectable mortality rate.Commoncomplications include infections, followed by impaired wound healing and bleeding. Bleeding and wound-healing issues are often associated with preexisting anticoagulation therapy, which is nonetheless managed safely duringMMS.We are not certain whether the small effects seen with the use of sterile gloves and antiseptics and antibiotics are clinically significant and whether wide-scale practice changeswould be cost-effective given the small risk reductions.
UR - http://www.scopus.com/inward/record.url?scp=84892172420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892172420&partnerID=8YFLogxK
U2 - 10.1001/jamadermatol.2013.6255
DO - 10.1001/jamadermatol.2013.6255
M3 - Article
C2 - 24080866
AN - SCOPUS:84892172420
SN - 2168-6068
VL - 149
SP - 1378
EP - 1385
JO - JAMA dermatology
JF - JAMA dermatology
IS - 12
ER -